Ans T van der Ploeg (A T van der Ploeg)

Publication Activity (10 Years)

Years Active: 2017-2024
Publications (10 Years): 20

Top Topics

Replacement Therapy

Cross Sectional

Top Venues

European journal of neurology

Clinical chemistry and laboratory medicine

Journal of inherited metabolic disease

Orphanet journal of rare diseases

This page only lists publications with an associated author ORCID identifier.

Publications

Sherif Bayoumy, Inge M W Verberk, Lisa Vermunt, Eline A J Willemse, Ben den Dulk, Ans T van der Ploeg, Dasja Pajkrt, Elisa Nitz, Johanna M P van den Hout, Julie van der Post, Nicole I Wolf, Shanice Beerepoot, Ewout Joan Nicolaas Groen, Victoria Tüngler, Charlotte E Teunissen
Neurofilament light protein as a biomarker for spinal muscular atrophy: a review and reference ranges. Clinical chemistry and laboratory medicine (2024)
Aglina Lika, Eleni-Rosalina Andrinopoulou, Nadine A M E van der Beek, Dimitris Rizopoulos, Ans T van der Ploeg, Michelle E Kruijshaar
Establishing how much improvement in lung function and distance walked is clinically important for adult patients with Pompe disease. European journal of neurology 31 (5) (2024)
Chloé F Najac, Nadine A M E van der Beek, Vincent Oltman Boer, Pieter A van Doorn, Ans T van der Ploeg, Itamar Ronen, Hermien E Kan, Johanna M P van den Hout
Brain glycogen build-up measured by magnetic resonance spectroscopy in classic infantile Pompe disease. Brain communications 6 (5) (2024)
Benedikt Schoser, Nadine A M E van der Beek, Alexander Broomfield, Esther Brusse, Jordi Díaz-Manera, Andreas Hahn, Thomas Hundsberger, Cornelia Kornblum, Michelle Kruijshaar, Pascal Laforêt, Eugen Mengel, Tiziana Mongini, David Orlikowski, Giancarlo Parenti, W W M Pim Pijnappel, Mark Roberts, Thomas Scherer, Antonio Toscano, John Vissing, Johanna M P van den Hout, Pieter A van Doorn, Stephan Wenninger, Ans T van der Ploeg
Start, switch and stop (triple-S) criteria for enzyme replacement therapy of late-onset Pompe disease: European Pompe Consortium recommendation update 2024. European journal of neurology (2024)
Harmke A van Kooten, Mike C Horton, Stephan Wenninger, Haris Babačić, Benedikt Schoser, Claire Lefeuvre, Najib Taouagh, Pascal Laforêt, Sonia Segovia, Jordi Díaz-Manera, Kristl G Claeys, Tiziana Mongini, Olimpia Musumeci, Antonio Toscano, Thomas Hundsberger, Esther Brusse, Pieter A van Doorn, Ans T van der Ploeg, Nadine A M E van der Beek, null null
Improving outcome measures in late onset Pompe disease: Modified Rasch-Built Pompe-Specific Activity scale. European journal of neurology (2024)
Benedikt Schoser, Nadine A M E van der Beek, Alexander Broomfield, Esther Brusse, Jordi Díaz-Manera, Andreas Hahn, Thomas Hundsberger, Cornelia Kornblum, Michelle Kruijshaar, Pascal Laforêt, Eugen Mengel, Tiziana Mongini, David Orlikowski, Giancarlo Parenti, W W M Pim Pijnappel, Mark Roberts, Thomas Scherer, Antonio Toscano, John Vissing, Johanna M P van den Hout, Pieter A van Doorn, Stephan Wenninger, Ans T van der Ploeg
Start, switch and stop (triple-S) criteria for enzyme replacement therapy of late-onset Pompe disease: European Pompe Consortium recommendation update 2024. European journal of neurology 31 (9) (2024)
Aglina Lika, Eleni-Rosalina Andrinopoulou, Nadine A M E van der Beek, Dimitris Rizopoulos, Ans T van der Ploeg, Michelle E Kruijshaar
Establishing how much improvement in lung function and distance walked is clinically important for adult patients with Pompe disease. European journal of neurology 31 (5) (2024)
Benedikt Schoser, Nadine A M E van der Beek, Alexander Broomfield, Esther Brusse, Jordi Díaz-Manera, Andreas Hahn, Thomas Hundsberger, Cornelia Kornblum, Michelle Kruijshaar, Pascal Laforêt, Eugen Mengel, Tiziana Mongini, David Orlikowski, Giancarlo Parenti, W W M Pim Pijnappel, Mark Roberts, Thomas Scherer, Antonio Toscano, John Vissing, Johanna M P van den Hout, Pieter A van Doorn, Stephan Wenninger, Ans T van der Ploeg
Start, switch and stop (triple-S) criteria for enzyme replacement therapy of late-onset Pompe disease: European Pompe Consortium recommendation update 2024. European journal of neurology 31 (9) (2024)
Aglina Lika, Eleni-Rosalina Andrinopoulou, Nadine A M E van der Beek, Dimitris Rizopoulos, Ans T van der Ploeg, Michelle E Kruijshaar
Establishing how much improvement in lung function and distance walked is clinically important for adult patients with Pompe disease. European journal of neurology (2024)
Sherif Bayoumy, Inge M W Verberk, Lisa Vermunt, Eline A J Willemse, Ben den Dulk, Ans T van der Ploeg, Dasja Pajkrt, Elisa Nitz, Johanna M P van den Hout, Julie van der Post, Nicole I Wolf, Shanice Beerepoot, Ewout Joan Nicolaas Groen, Victoria Tüngler, Charlotte E Teunissen
Neurofilament light protein as a biomarker for spinal muscular atrophy: a review and reference ranges. Clinical chemistry and laboratory medicine 62 (7) (2024)
Benedikt Schoser, Nadine A M E van der Beek, Alexander Broomfield, Esther Brusse, Jordi Díaz-Manera, Andreas Hahn, Thomas Hundsberger, Cornelia Kornblum, Michelle Kruijshaar, Pascal Laforêt, Eugen Mengel, Tiziana Mongini, David Orlikowski, Giancarlo Parenti, W W M Pim Pijnappel, Mark Roberts, Thomas Scherer, Antonio Toscano, John Vissing, Johanna M P van den Hout, Pieter A van Doorn, Stephan Wenninger, Ans T van der Ploeg
Start, switch and stop (triple-S) criteria for enzyme replacement therapy of late-onset Pompe disease: European Pompe Consortium recommendation update 2024. European journal of neurology 31 (9) (2024)
Aglina Lika, Eleni-Rosalina Andrinopoulou, Nadine A M E van der Beek, Dimitris Rizopoulos, Ans T van der Ploeg, Michelle E Kruijshaar
Establishing how much improvement in lung function and distance walked is clinically important for adult patients with Pompe disease. European journal of neurology 31 (5) (2024)
Sherif Bayoumy, Inge M W Verberk, Lisa Vermunt, Eline A J Willemse, Ben den Dulk, Ans T van der Ploeg, Dasja Pajkrt, Elisa Nitz, Johanna M P van den Hout, Julie van der Post, Nicole I Wolf, Shanice Beerepoot, Ewout Joan Nicolaas Groen, Victoria Tüngler, Charlotte E Teunissen
Neurofilament light protein as a biomarker for spinal muscular atrophy: a review and reference ranges. Clinical chemistry and laboratory medicine 62 (7) (2024)
Imke A M Ditters, Harmke A van Kooten, Nadine A M E van der Beek, Jacqueline F Hardon, Gamida Ismailova, Esther Brusse, Michelle E Kruijshaar, Ans T van der Ploeg, Johanna M P van den Hout, Hidde H Huidekoper
Home-Based Infusion of Alglucosidase Alfa Can Safely be Implemented in Adults with Late-Onset Pompe Disease: Lessons Learned from 18,380 Infusions. BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy (2023)
Meng Yuan, Eleni-Rosalina Andrinopoulou, Michelle E Kruijshaar, Aglina Lika, Laurike Harlaar, Ans T van der Ploeg, Dimitris Rizopoulos, Nadine A M E van der Beek
Positive association between physical outcomes and patient-reported outcomes in late-onset Pompe disease: a cross sectional study. Orphanet journal of rare diseases 15 (1) (2020)
Esther Poelman, Jan J A van den Dorpel, Marianne Hoogeveen-Westerveld, Johanna M P van den Hout, Lianne J van der Giessen, Nadine A M E van der Beek, W W M Pim Pijnappel, Ans T van der Ploeg
Effects of higher and more frequent dosing of alglucosidase alfa and immunomodulation on long-term clinical outcome of classic infantile Pompe patients. Journal of inherited metabolic disease 43 (6) (2020)
E Poelman, M Hoogeveen-Westerveld, J M P van den Hout, R G M Bredius, A C Lankester, G J A Driessen, S S M Kamphuis, W W M Pijnappel, Ans T van der Ploeg
Effects of immunomodulation in classic infantile Pompe patients with high antibody titers. Orphanet journal of rare diseases 14 (1) (2019)
Jan C van der Meijden, Michelle E Kruijshaar, Laurike Harlaar, Dimitris Rizopoulos, Nadine A M E van der Beek, Ans T van der Ploeg
Long-term follow-up of 17 patients with childhood Pompe disease treated with enzyme replacement therapy. Journal of inherited metabolic disease 41 (6) (2018)
Esther Kuperus, Jan C van der Meijden, Stijn L M In 't Groen, Marian A Kroos, Marianne Hoogeveen-Westerveld, Dimitris Rizopoulos, Monica Yasmin Nino Martinez, Michelle E Kruijshaar, Pieter A van Doorn, Nadine A M E van der Beek, Ans T van der Ploeg, W W M Pim Pijnappel
The ACE I/D polymorphism does not explain heterogeneity of natural course and response to enzyme replacement therapy in Pompe disease. PloS one 13 (12) (2018)
Ans T van der Ploeg, M E Kruijshaar, A Toscano, P Laforêt, C Angelini, R H Lachmann, S I Pascual Pascual, M Roberts, K Rösler, T Stulnig, P A van Doorn, P Y K Van den Bergh, J Vissing, B Schoser, null null
European consensus for starting and stopping enzyme replacement therapy in adult patients with Pompe disease: a 10-year experience. European journal of neurology 24 (6) (2017)